Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy
NCT ID: NCT04663672
Last Updated: 2020-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
158 participants
INTERVENTIONAL
2019-01-29
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present study will will provide a rigorous test of TMR's efficacy as an augmentative strategy for exposure therapy. It is hypothesized that participants who sleep in the presence of the same odor that they are exposed to during exposure therapy will exhibit reduced fear at follow up, relative to participants who sleep in the presence of a different odor, or a non-odorous control.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure Therapy + Exposure Scent Cue During Sleep
Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of the exposure scent.
Experimental Scent
Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
In-Vivo Exposure
Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Exposure Therapy + Novel Scent During Sleep
Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of a novel scent.
Control Scent
Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
In-Vivo Exposure
Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Exposure Therapy + No-Scent Control During Sleep
Participants will undergo exposure treatment for their target fear while in the presence of a distinctive odor. Exposure will occur in repeated 4-minute trials. Exposure will continue for 40 minutes or until peak fear decreases by at least 35 points on a 100 point scale, compared to peak fear during the initial trial. Participants will subsequently sleep in the presence of an odorless control vehicle.
No-Scent Control
Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
In-Vivo Exposure
Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental Scent
Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
Control Scent
Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
No-Scent Control
Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
In-Vivo Exposure
Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. self-reported peak anxiety of at least 50 on a 100 point scale in response to two behavioral approach tasks
2. self-report measures meeting the following cutoffs for the target fear:
* Fear of Spiders Questionnaire ≥ 50
* Obsessive-Compulsive Inventory-Revised (Washing Subscale) ≥ 4
* Claustrophobia Screener ≥ 2
Exclusion Criteria
* Current sleep medication usage
* Inability to differentiate two different odors from an indoor scent diffuser
* Current psychotherapy for fear of spiders, snakes, enclosed spaces, or contamination
* Current use of air fresheners, scented candles, or other items with odors related to those used in the study
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael J. Telch
Prinicipal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory for the Study of Anxiety Disorders, University of Texas at Austin
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-09-0058
Identifier Type: -
Identifier Source: org_study_id